Press corner
Latest news
Neorphys closes its 1st seed financing round. A first financing round of 1.05 M€ has been achieved in 2007 and 2008 with Inserm Transfert Initiative, Soridec and CEA Valorisation. It will be used to pursue the development of NEO1509, the lead analgesic drug candidate for visceral pain, up to regulatory preclinical studies and to expand its pain pipeline in other pain areas.
New French patent filed on April 2007, extended on April 2008, covering a new series of novel melanocortine agonists designed, synthesized and validated in vitro to date by the Neorphys scientists (patent FR-07/54279).
Neorphys gets a grant from Oseo Anvar and a grant from Crealia - Neorphys has obtained a 210K€ grant to support its innovative projects from Oseo Anvar and the Languedoc Roussilllon Regional Council and a 38K€ grant from Crealia.
Neorphys gets a grant from Europe and the Languedoc-Roussillon region - Neorphys has obtained a financial support from the European Union (European Fund of Regional Development) and the Languedoc Roussillon Regional Counsil for its innovative research programs.
Press coverage
- Neorphys - IndustriePharma n° 29 – 09/2007
- Neorphys : une stratégie basée sur deux domaines thérapeutiques - Biofutur n° 279 - 07/2007
- Neorphys finalise sa levée d’amorçage - Info Veille Biotech n°103– 25/04/2007
- Neorphys amorce la pompe à financement - BioPharmaceutiques n° 19 – 12/04/2007
- Update from Neorphys - R&D Focus Drug News Volume 16 n° 41 – 08/10/2006
- Neorphys combat la douleur aiguë - Soridec Newsletter – Automne 2007
- Au bord de l'orgasme - Libération (Sandrine Cabut) - 08/07/2006
- Neorphys : Un brevet nommé désir - Biotech Info n° 308 (François Anger) - 12/04/2006
Press releases
Neorphys closes its 1st financing round. A
first financing round of 1.05 M€ has been achieved in 2007
with Inserm Transfert Initiative, Soridec and CEA Valorisation (VCs).
It will be used to pursue the development of the analgesic drug
candidate up to the start of regulatory preclinical studies and to make
possible an animal assay for Neorphys second therapeutic axis, female
sexual dysfunction.
Download press release - pdf (56kb)
Télécharger
le communiqué - pdf (49kb)
